Risk assessment and cost-effectiveness/utility analysis

被引：13

作者：

Busch, Michael ^{[1
,2
]}

Walderhaug, Mark ^{[3
]}

Custer, Brian ^{[4
]}

Allain, Jean-Pierre ^{[5
]}

Reddy, Ravi ^{[6
]}

McDonough, Brian ^{[7
]}

机构：

[1] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA

[3] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA

[4] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA

[5] Univ Cambridge, Dept Haematol, Cambridge, England

[6] S African Natl Blood Serv, Johannesburg, South Africa

[7] Orthoclin Diagnost, Raritan, NJ USA

来源：

BIOLOGICALS | 2009年 / 37卷 / 02期

关键词：

Public health; Policy making; Blood; Transfusions; WEST-NILE-VIRUS; BLOOD-TRANSFUSION; VIRAL MARKERS; UNITED-STATES; HEPATITIS-B; RAPID TESTS; DONATIONS; AFRICA; DONORS; HEALTH;

D O I：

10.1016/j.biologicals.2009.01.007

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Decisions are usually guided by immediately available information and a significant amount of experience and judgment. For decisions concerning familiar situations and common problems, judgment and experience may work quite well, but this type of decision process can lack clarity and accountability. Public health challenges are changing as emerging diseases and expensive technologies complicate the decision-makers' task. confronting the decision-maker with new problems that include multiple potential Solutions. Decisions regarding polices and adoption of technologies are particularly complex in transfusion medicine clue to the scope of the field, implications for public health, and legal, regulatory and public expectations regarding blood safety. To assist clecision-makerS, quantitative risk assessment and cost-effectiveness analysis Lire now being more widely applied. This set of articles will introduce risk assessment and cost-effectiveness methodologies and discuss recent applications of these methods in transfusion medicine. (C) 2009 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 34 条

[1] Rapid tests for detection of viral markers in blood transfusion [J].

Allain, JP ;

Lee, H .

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (01) :31-41

[2] A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion [J].

AuBuchon, JP ;

Littenberg, B .

TRANSFUSION, 1996, 36 (03) :222-226

[3] Donor mobilization experiences of the kenya red cross society [J].

Bates, I. ;

Manyasi, G. ;

Lara, A. Medina .

TRANSFUSION MEDICINE, 2007, 17 (06) :434-442

[4] Blood management: A primer for clinicians [J].

Boucher, Bradley A. ;

Hannon, Timothyj. .

PHARMACOTHERAPY, 2007, 27 (10) :1394-1411

[5] A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors [J].

Busch, MP ;

Glynn, SA ;

Stramer, SL ;

Strong, DM ;

Caglioti, S ;

Wright, DJ ;

Pappalardo, B ;

Kleinman, SH .

TRANSFUSION, 2005, 45 (02) :254-264

[6] Balancing evidence and public opinion in health technology assessments: The case of leukoreduction [J].

Cleemput, Irina ;

Leys, Mark ;

Ramaekers, Dirk ;

Bonneux, Luc .

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (04) :403-407

[7]

*COMM I MEANS ASS, 1983, RISK ASS FED GOV MAN

[8]

*CTR BIOL EV RES, 2006, DRAFT QUANT RISK ASS

[9] The cost-effectiveness of screening the u.S. blood supply for West Nile virus [J].

Custer, B ;

Busch, MP ;

Marfin, AA ;

Petersen, LR .

ANNALS OF INTERNAL MEDICINE, 2005, 143 (07) :486-492

[10] Transfusion in sub-Saharan Africa: does a Western model fit? [J].

Field, Stephen P. ;

Allain, Jean-Pierre .

JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (10) :1073-1075

← 1 2 3 4 →